Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
Clinical trial NCT05650216 · UNKNOWN
Trial details
- NCT number
- NCT05650216
- Sponsor
- Shanghai Chest Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-25
- Primary completion
- 2023-12-25
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.